BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37072838)

  • 1. Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy.
    Talebi A; de Laat V; Spotbeen X; Dehairs J; Rambow F; Rogiers A; Vanderhoydonc F; Rizotto L; Planque M; Doglioni G; Motamedi S; Nittner D; Roskams T; Agostinis P; Bechter O; Boecxstaens V; Garmyn M; O'Farrell M; Wagman A; Kemble G; Leucci E; Fendt SM; Marine JC; Swinnen JV
    J Exp Clin Cancer Res; 2023 Apr; 42(1):92. PubMed ID: 37072838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.
    Talebi A; Dehairs J; Rambow F; Rogiers A; Nittner D; Derua R; Vanderhoydonc F; Duarte JAG; Bosisio F; Van den Eynde K; Nys K; Pérez MV; Agostinis P; Waelkens E; Van den Oord J; Fendt SM; Marine JC; Swinnen JV
    Nat Commun; 2018 Jun; 9(1):2500. PubMed ID: 29950559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
    Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.
    Wang L; Leite de Oliveira R; Huijberts S; Bosdriesz E; Pencheva N; Brunen D; Bosma A; Song JY; Zevenhoven J; Los-de Vries GT; Horlings H; Nuijen B; Beijnen JH; Schellens JHM; Bernards R
    Cell; 2018 May; 173(6):1413-1425.e14. PubMed ID: 29754815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
    Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M
    Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies.
    Didier R; Mallavialle A; Ben Jouira R; Domdom MA; Tichet M; Auberger P; Luciano F; Ohanna M; Tartare-Deckert S; Deckert M
    Mol Cancer Ther; 2018 Jul; 17(7):1416-1429. PubMed ID: 29703842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma.
    Pisanu ME; Maugeri-Saccà M; Fattore L; Bruschini S; De Vitis C; Tabbì E; Bellei B; Migliano E; Kovacs D; Camera E; Picardo M; Jakopin Z; Cippitelli C; Bartolazzi A; Raffa S; Torrisi MR; Fulciniti F; Ascierto PA; Ciliberto G; Mancini R
    J Exp Clin Cancer Res; 2018 Dec; 37(1):318. PubMed ID: 30558661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.
    Caenepeel S; Cooke K; Wadsworth S; Huang G; Robert L; Moreno BH; Parisi G; Cajulis E; Kendall R; Beltran P; Ribas A; Coxon A; Hughes PE
    Oncotarget; 2017 Mar; 8(11):17795-17809. PubMed ID: 28147313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma.
    Girard CA; Lecacheur M; Ben Jouira R; Berestjuk I; Diazzi S; Prod'homme V; Mallavialle A; Larbret F; Gesson M; Schaub S; Pisano S; Audebert S; Mari B; Gaggioli C; Leucci E; Marine JC; Deckert M; Tartare-Deckert S
    Cancer Res; 2020 May; 80(10):1927-1941. PubMed ID: 32179513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
    Lassen A; Atefi M; Robert L; Wong DJ; Cerniglia M; Comin-Anduix B; Ribas A
    Mol Cancer; 2014 Apr; 13():83. PubMed ID: 24735930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.
    Guo S; Yue Q; Wang S; Wang H; Ye Z; Zhang W; Shi Q; Gao T; Li C; Zhu G
    J Dermatol Sci; 2023 Feb; 109(2):52-60. PubMed ID: 36858850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
    Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
    Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
    Byron SA; Loch DC; Wellens CL; Wortmann A; Wu J; Wang J; Nomoto K; Pollock PM
    Mol Cancer; 2012 Oct; 11():75. PubMed ID: 23039341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization.
    Fattore L; Malpicci D; Milite C; Castellano S; Sbardella G; Botti G; Ascierto PA; Mancini R; Ciliberto G
    Cell Commun Signal; 2020 Sep; 18(1):150. PubMed ID: 32933538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.
    Wong DJ; Robert L; Atefi MS; Lassen A; Avarappatt G; Cerniglia M; Avramis E; Tsoi J; Foulad D; Graeber TG; Comin-Anduix B; Samatar A; Lo RS; Ribas A
    Mol Cancer; 2014 Aug; 13():194. PubMed ID: 25142146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
    Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
    Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Spry1 reduces growth of BRAF
    Montico B; Colizzi F; Giurato G; Rizzo A; Salvati A; Baboci L; Benedetti D; Pivetta E; Covre A; Bo MD; Weisz A; Steffan A; Maio M; Sigalotti L; Fratta E
    Cell Death Dis; 2020 May; 11(5):392. PubMed ID: 32444628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.
    Eichhoff OM; Stoffel CI; Käsler J; Briker L; Turko P; Karsai G; Zila N; Paulitschke V; Cheng PF; Leitner A; Bileck A; Zamboni N; Irmisch A; Balazs Z; Tastanova A; Pascoal S; Johansen P; Wegmann R; Mena J; Othman A; Viswanathan VS; Wenzina J; Aloia A; Saltari A; Dzung A; ; Krauthammer M; Schreiber SL; Hornemann T; Distel M; Snijder B; Dummer R; Levesque MP
    Cancer Res; 2023 Apr; 83(7):1128-1146. PubMed ID: 36946761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.